Oncolytic virus preclinical toxicology studies.
J Appl Toxicol
; 43(5): 620-648, 2023 05.
Article
em En
| MEDLINE
| ID: mdl-36299168
ABSTRACT
With the ever-emerging concerns of patient safety during medical care, the search for treatments as safe as possible is a priority, especially when focusing on cancer treatment of which therapies often go hand in hand with severe side effects. Oncolytic virotherapy is an emerging treatment for cancer that is promising in both safety and efficacy. Many currently ongoing clinical trials demonstrate the growing interest in this field. To conduct clinical trials, preclinical studies are mandatory; however, there are not many reviews of toxicology studies on oncolytic virus therapies. This article summarizes the preclinical toxicology studies of the most well studied oncolytic viruses, including Oncorine, Talimogene laherparepvec, Cavatak, ONYX-015, teserpaturev and Rigvir, a non-pathogenic ECHO-7 virus. It is concluded that oncolytic viruses have been shown to have low toxicity and high tolerability in preclinical toxicology studies.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Vírus Oncolíticos
/
Terapia Viral Oncolítica
/
Melanoma
Limite:
Humans
Idioma:
En
Revista:
J Appl Toxicol
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Letônia